Tumor necrosis factor α and human Schwann cells: Signalling and phenotype modulation without cell death

Journal of Neuropathology and Experimental Neurology

Volumn 59, Issue 1, 2000, Pages 74-84

  Bonetti, Bruno ^a   Valdo, Paola ^b   Stegagno, Chiara ^b   Tanel, Raffaella ^b   Zanusso, Gianluigi ^b   Ramarli, Dunia ^b   Fiorini, Emma ^b   Turazzi, Sergio ^b   Carner, Marco ^b   Moretto, Giuseppe ^b  

^a POLICLINICO BORGO ROMA   (Italy)

^b NONE

Author keywords

C jun; De differentiation; NF B; NGF receptor; Schwann cells; TNF ; Transcription factors

Indexed keywords

ACETYLSALICYLIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NERVE GROWTH FACTOR RECEPTOR; PROTEIN C JUN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; GENETIC TRANSCRIPTION; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MODULATION; PHENOTYPE; PRIORITY JOURNAL; SCHWANN CELL; SIGNAL TRANSDUCTION;

EID: 0033980131     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/59.1.74     Document Type: Article

References (42)

1. Bazzoni F, Beutler B. How do tumor necrosis factor receptors work? J Inflamm 1995;45:221-38
2. Vandanabeele P, Declercq W, Beyaert R, Fiers W. Two tumor necrosis factor receptors: Structure and functions. Trends Biochem Sci 1995;5:392-99
3. Bauerle PA, Baltimore D. NFκB: Ten years later. Cell 1996;87: 13-20
4. Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK is not linked to apoptosis while NFκB activation prevents cell death. Cell 1996;87:565-76
5. Grilli MG, Chiu JJ, Lenardo MJ. NFκB and Rel: Participants in a multiform transcriptional regulatory system. Int Rev Cytol 1993;143:1-62
6. O'Neill LAJ, Kaltschmidt C. NFκB: A crucial transcription factor for glial and neuronal cell function. Trends Neurol Sci 1997;20: 252-58
7. Herdegen T, Skene P, Bahr M. The c-jun transcription factor-bipotential mediator of neuronal death, survival and regeneration. Trends Neurol Sci 1997;20:227-31
8. Kyriakis JM, Banerjee P, Nikolakaki E, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994;369: 156-60
9. Hartung HP, Jung S, Stoll G, et al. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol 1992;40:197-210
10. rd edition. Philadelphia: Saunders, 1993:418-44
11. Raine CS. The Dale E. McFarlin memorial lecture: The immunology of the multiple sclerosis lesion. Ann Neurol 1994;36:561-72
12. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989;170: 607-12
13. Oka N, Akiguchi I, Kawasaki T, et al. Tumor necrosis factor α in peripheral nerve lesions. Acta Neuropathol 1998;95:57-62
14. Selmaj KW, Raine CS, Cannella B, Brosnan CF Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991;87:949-54
15. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23:339-46
16. Wilt SG, Milward E, Zhou JM, et al. In vitro evidence for a dual role of tumor necrosis factor-α in human immunodeficency virus type-I encephalopathy. Ann Neurol 1995;37:381-94
17. Chandross KJ, Spray DC, Cohen RI, et al. TNFα inhibits Schwann cell proliferation, connexin46 expression, and gap junctional communication. Mol Cell Neurosci 1996;7:479-500
18. Schneider-Schaulies J, Kirchhof F, Archelos J, Schachner M. Down-regulation of myelin-associated glycoprotein on Schwann cells by interferon-γ and tumor necrosis factor-α affects neurite outgrowth. Neuron 1991;7:995-1005
19. Skoff AM, Lisak RP, Bealmear B, Benjamins JA. TNF-α and TGF-α act synergistically to kill Schwann cells. J Neurosci Res 1998;53: 747-56
20. Mirsky R, Jessen KR. The neurobiology of Schwann cells. Brain Pathol 1999;9:293-311
21. Scherer SS. The biology and pathobiology of Schwann cells. Curr Opin Neurol 1997;10:386-97
22. Guenard V, Montay D, Schachner M, Martini R. Onion bulb cells in mice deficient for myelin genes share molecular properties with immature, differentiated non-myelinating, and denervated Schwann cells. Glia 1996;18:27-38
23. Quattrini A, Previtali S, Feltri ML, et al. Beta 4 integrin and other Schwann cell markers in axonal neuropathy. Glia 1996;17:294-306
24. Cheng L, Mudge AW. Cultured Schwann cells constitutively express the myelin protein P0. Neuron 1996;16:309-19
25. Sasagasato N, Toda K, Hollis M, Quarles RH. Myelin gene expression in immortalized Schwann cells: relationship to cell density and proliferation. J Neurochem 1996;66:1432-39
26. Bonetti B, Panzeri L, Carner M, et al. Human neoplastic Schwann cells: Changes in the expression of neurotrophins and their low-affinity receptor p75. Neuropathol Appl Neurobiol 1997;23:380-86
27. Kuruvilla R, Eichberg J. Depletion of phospholipid arachidonoyl-containing molecular species in a human Schwann cell line grown in elevated glucose and their restoration by an aldose reductase inhibitor. J Neurochem 1998;71:775-83
28. Scarpini E, Kreider BQ, Lisak LP, et al. Cultures of human Schwann cells isolated from fetal nerves. Brain Res 1988;440: 261-66
29. Dyck PJ, Prineas J, Pollard J. Chronic inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, eds. Peripheral neuropathy. 3rd Ed. Philadelphia: Saunders, 1993;1498-1517
30. Ilyas AA, Quarles RH, MacIntosh TD, et al. IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate deter minant in the myelin-associated glycoprotein and to a ganglioside. Proc Natl Acad Sci USA 1984;81:1225-29
31. Monaco S, Ferrari S, Bonetti B, et al. Experimental induction of myelin changes by anti-MAG antibodies and terminal complement complex. J Neuropathol Exp Neurol 1995;54:96-104
32. Nobile-Orazio E, Hays AP, Latov N, et al. Specificity of mouse and human monoclonal antibodies to myelin-associated glycoprotein. Neurology 1984;34:1336-42
33. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with mini-extracts prepared from a small number of cells. Nucleic Acid Res 1989;17:6419-22
34. Ramarli D, Scupoli MT, Fiorini E, et al. Thymocyte contact or monoclonal antibody-mediated clustering of α3β1 or α6β4 integrins activate interleukin-6 (IL-6) transcription factors (NF-κB and NF-IL6) and IL-6 production in human thymic epithelial cells. Blood 1998;92:3745-55
35. Kopp E, Ghosh S. Inhibition of NFκB by sodium salicylate and aspirin. Science 1994;265:956-59
36. Grilli MG, Pizzi M, Memo M, Spano PF. Neuroprotection by aspirin and sodium salicylate through blockade of NFκB activation. Science 1996;274:1383-85
37. Carter BD, Kaltschmidt C, Kaltschmidt B, et al. Selective activation of NFκB by nerve growth factor through the neurotrophin receptor p75. Science 1996;272:542-45
38. Jessen KR, Brennan A, Morgan L, et al. The Schwann cell precursor and its fate: A study of cell death and differentiation during gliogenesis in rat embryonic nerves. Neuron 1991;12:509-27
39. Beg AA, Baltimore D. An essential role for NFκB in preventing TNF-α-induced cell death. Science 1996;274:782-84
40. Van Antwerp D, Martin S, Kafri T, et al. Suppression of TNF-α-induced apoptosis by NFκB. Science 1996;274:787-89
41. Wang CY, Mayo M, Baldwin A. TNF- and cancer therapy-induced apoptosis potentiation by inhibition of NFκB. Science 1996;274: 784-87
42. Bonetti B, Stegagno C, Cannella B, et al. Activation of NFκB and c-jun transcription factors in MS lesions: Implications for oligodendrocyte pathology. Am J Pathol (in press).